MLASC-based therapies

About Celularity

Celularity is a leader in regenerative and cellular medicine, harnessing the unique biology of the postpartum placenta to create a scalable pipeline of allogeneic cell therapies and biomaterial products. With a deep scientific foundation spanning over two decades, the company has transitioned from its origins as Anthrogenesis (founded 1998) to a publicly traded entity with a robust clinical pipeline and commercial capabilities. Its strategy focuses on overcoming traditional barriers in cell therapy—scale, quality, and economics—to deliver effective, off-the-shelf treatments for serious conditions, supported by a seasoned leadership team and integrated manufacturing infrastructure.

Therapeutic Areas